Biohaven: Phase 2 Proof-of-concept Study With BHV-7000 Fails To Meet Primary Endpoint

December 25, 2025 — 06:25 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Biohaven (BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder. The study did not meet its primary endpoint, a reduction of depressive symptoms as measured by change in the Montgomery Åsberg Depression Rating Scale over six weeks compared with placebo.

The company noted that trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures. Additional analyses are ongoing and the company plans to present the results at an upcoming scientific meeting.

Shares of Biohaven were down 16% after hours on Wednesday.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Biohaven: Phase 2 Proof-of-concept Study With BHV-7000 Fails To Meet Primary Endpoint

Tags

Latest Articles